Terns Pharmaceuticals said on Tuesday it will stop developing its experimental obesity drug after a mid-stage trial showed modest weight loss and raised safety concerns.

Celcuity expects to complete a rolling NDA submission for gedatolisib under the FDA RTOR program by Q4 2025. Click here to ...

According to new data, 73% of all participants in treatment courts did not commit another felony offense within five years of ...

A lapse in funding due to the shutdown could have a devastating effect on the millions of Americans who rely on the federal ...

The B.S. degree launched this fall as part of a long-term plan that began in 2017 with local industry approaching UNLV to ...

MO’ DOUGH FO’ CUO: Brooklyn neighborhoods with large Jewish communities along with the Upper West and Upper East sides of ...

Walmart's move comes after the Trump administration last month introduced a $100,000 fee for new H-1B applications to ...

In President Donald Trump’s America, information that has been relied on for decades to make critical decisions has been ...

The U.S. Department of Agriculture will not pay out Supplemental Nutrition Assistance Program (SNAP) in November if the ...

Texas officials identify over 2,700 possible illegal immigrants registered to vote, sending cases to counties for 30-day ...

After comparing the 18 million voter list names with the SAVE database, 2,724 potential noncitizens who are registered to ...

In a series of letters to administration officials, the Democrats, led by Sen. Patty Murray, D-Wash., the party’s top ...